Can Androgen Therapy Replete Lean Body Mass and Improve Muscle Function in Wasting Associated with Human Immunodeficiency Virus Infection?

Journal of Parenteral and Enteral Nutrition

Volumn 23, Issue 6_suppl, 1999, Pages S195-S201

  Bhasin, Shalender ^a   Javanbakht, Marjan ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

ANDROGEN THERAPY; BIOSYNTHESIS; BODY COMPOSITION; CONFERENCE PAPER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEAN BODY WEIGHT; LIPID METABOLISM; MALE; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE MASS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; WEIGHT REDUCTION; DRUG EFFECT; HORMONAL THERAPY; MUSCLE STRENGTH;

ANDROGENS; BODY COMPOSITION; FEMALE; HIV WASTING SYNDROME; HUMANS; MALE; MUSCLE, SKELETAL; PROGNOSIS; TESTOSTERONE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032729340     PISSN: 01486071     EISSN: 19412444     Source Type: Journal    
DOI: 10.1177/014860719902300605     Document Type: Conference Paper

References (83)

1. Hellerstein MK, Kahn J., Mundi H., et al. Current approach to treatment of human immunodeficiency virus associated with weight loss, pathophysiologic considerations and emerging strategies. Sem Oncol 17: 17-33, 1990
2. Kotler DP, Tierney AR, Wang J., et al. Magnitude of body cell mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 50: 444-447, 1989
3. Grunfeld C., Feingold KR: Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 327: 329-337, 1992
4. Sellmeyer DE, Grunfeld C.: Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 17: 518-32, 1996
5. Chlebowski RT, Grosvenor MB, Bernhard NH, et al. Nutritional status, gastrointestinal dysfunction and survival in patients with AIDS. Am J Gastroenterol 84: 1288-1293, 1989
6. Salehian B., Jacobson D., Swerdloff RS, et al. Testicular pathology and pituitary-Testicular axis during HIV infection. Endocrine Practice 5: 1-10, 1999
7. Nahlen BL, Chu SY, Nwanyanwu O. c, et al. HIV wasting syndrome in the United States. AIDS 7: 183-188, 1993
8. Dobs AS, Few WL, Blackman MR, et al. Serum hormones in men with human immunodeficiency virus-Associated wasting. J Clin Endocrinol Metab 81: 4108-4112, 1996
9. Grinspoon S., Corcoran C., Lee K., et al. Loss of lean body and muscle mass correlates with androgen levels in hypogondal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 81: 4051-4058, 1996
10. Linden CP, Allen S., Serufilira A., et al. Predictors of mortality among HIV-infected women in Kigali, Rwanda. Ann Intern Med 116: 320-325, 1992
11. Gunter PA, Mourahainen N., Cohen GR, et al. Relationship between nutritional status. CD4 counts and survival in HIV infection. Am J Clin Nutr 56: 762-799, 1992
12. Bhasin S., Bremner WJ: Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab 82: 3-8, 1997
13. Sokol RZ, Palacios A., Campfield LA, et al. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 37: 425-430, 1982
14. Snyder PJ, Lawrence DA: Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 51: 1335-1339, 1980
15. Matsumoto AM: Effects of chronic testosterone administration in normal men: safety and efficacy of high dose testosterone and parallel dose-dependent suppression of LH, FSH and sperm production. J Clin Endocrinol Metab 70: 282-287, 1990
16. Meikle AW, Mazer NA, Moellmer JF, et al. Enhanced transdermal delivery of testosterone across the nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 74: 623-628, 1992
17. Wilson JD: Androgen abuse by athletes. Endocr Rev 9: 181-200, 1988
18. Bardin CW: The anabolic action of testosterone. N Engl J Med 335: 52-53, 1996
19. Casaburi R., Storer T. Bhasin S.: Androgen effects on body composition and muscle performance. IN Pharmacology. Biology, and Clinical Applications of Androgens: Current Status and Future Prospects. Bhasin S. Gabelnick H. Spieler JM. et al (eds). Wiley-Liss, New York, 1996. pp 283-288
20. Mooradian AD Morley JE, Korenman SG: Biological actions of androgens. Endocr Rev 8: 1-28, 1987
21. Bhasin S., Storer TW, Berman N., et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in men. N Engl J Med 335: 1-7. 1996
22. Kenyon AT, Knowlton K., Sandiford I., et al. A comparative study of the metabolic effects of testosterone propionate in normal men and women and in eunuchoidism. Endocrinology 26: 26-45, 1940
23. Kochakian CD: Comparison of protein anabolic properties of various androgens in the castrated rat. Am J Physiol 60: 553-558, 1950
24. Bhasin S., Storer TW, Berman N., et al. A replacement dose of testosterone increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 82: 407-413, 1997
25. Brodsky IG, Balagopal P., Nair KS: Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men-A Clinical Research Center study. J Clin Endocrinol Metab 81: 3469-3475, 1996
26. Wang C., Eyre DR, Clark R., et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone resorption markers in hypogonadal men-A Clinical Research Center study. J Clin Endocrinol Metab 81: 3654-3662, 1996
27. Katznelson L., Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81: 4358-4365, 1996
28. Bhasin S., Tenover JS: Sarcopenia: Issues in testosterone replacement of older men. J Clin Endocrinol Metab 82: 1659-1660, 1997
29. Forbes GB, Porta CR, Herr B., et al. Sequence of changes in body composition induced by testosterone and reversal of changes after the drug is stopped. JAMA 267: 397-399, 1992
30. Griggs RC, Kingston W., Josefowicz RF, et al. Effect of testosterone on muscle mass and muscle protein synthesis. J Appl Physiol 66: 498-503, 1989
31. Griggs RC, Pandya S., Florence JM, et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology 39: 219-222, 1989
32. Urban RJ, Bodenburg YH, Gilkison C., et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 269: E820-E826, 1995
33. Young NR, Baker HWG, Liu G., et al. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception. J Clin Endocrinol Metab 77: 1028-1032, 1993
34. Arver SA, Sinha-Hikim I., Beall G., et al. Serum dihydrotestosterone and testosterone levels in human immunodeficiency virus infected men with or without weight loss. J Androl 20: 611-617, 1999
35. Dobs AS, Dempsey MA, Ladenson PW, et al. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 84: 611-615, 1988
36. Meremich JA, McDermott MT, Asp AA, et al. Evidence of endocrine involvement early in the course of human immunodeficiency virus infection. J Clin Endocrinol Metab 70: 566-571, 1990
37. Villete JM, Bourin P., Dornel C., et al. Circadian variations in plasma levels of hypophyseal, adrenocortical, and testicular hormones in men infected with human immunodeficiency virus. J Clin Endocrinol Metab 70: 572-577, 1990
38. Aron DC: Endocrine complications of the acquired immunodeficiency syndrome. Arch Intern Med 149: 330-333, 1989
39. Croxon TC, Chapman WE, Miller LK, et al. Changes in the hypothalamic pituitary-gonadal axis in human immunodeficiency virus-infected hypogonadal men. J Clin Endocrinol Metab 68: 317-321. 1989
40. Raffi F., Brisseau J-M., Planchon B., et al. Endocrine function in 98 HIV-infected patients: A prospective study. AIDS 5: 729-733, 1991
41. DePaepe ME, Vuletin JC Lee MH, et al. Testicular atrophy in homosexual AIDS patients. Hum Pathol 20: 572-578. 1989
42. Meyer-Bahlburg FH, et al. HIV positive gay men: Sexual dysfunction (Abstr). Proc VI International Conference on AIDS 1989, p 701
43. Coodley GO, Loveless MO Nelson HD, et al. Endocrine function in HIV wasting syndrome. J Acquir Immune Defic Syndr Retrovirol 7: 46-51. 1994
44. Laudet A., Blum L., Guechot J., et al. Changes in systematic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: Relationship with CD4 counts. Eur J Endocrinol 133: 418-424, 1995
45. Casaburi R., Goren S., Bhasin S.: Substantial prevalence of low anabolic hormone levels in COPD patients undergoing rehabilitation [Abstr]. Am J Respir Crit Care Med 153: A128, 1996
46. Handelsman DJ, Dong Q.: Hypothalamic-pituitary gonadal axis in chronic renal failure. Endocrinol Metab Clin North Am 22: 145-161, 1993
47. Rabkin JG, Rabkin R., Wagner GJ: Testosterone treatment of clinical hypogonadism in patients with HIV/AIDS. Int J STD AIDS 8: 537-545, 1997
48. Beal JE, Oldson R., Laubenstein L., et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10: 89-97, 1995
49. Von Roenn JH, Armstrong D., Kotler DP, et al. Megastrol acetate in patients with AIDS-related cachexia. Ann Intern Med 121: 393-399, 1994
50. Schambelan M., Mulligan K., Grunfeld C., et al. Recombinant growth hormone in patients with HIV-Associated wasting. Ann Intern Med 125: 873-882, 1996
51. Waters D., Danska J., Hardy K., et al. Recombinant growth hormone, insulin-like growth factor-1, and combination therapy in AIDS-Associated wasting. Ann Intern Med 125: 865-872, 1996
52. Bucher G., Berger DS, Fields-Gardner C., et al. A prospective study on the safety and effect of nandrolone decanoate in HIV positive patients [Abstr]. Int Conf AIDS 11: 26, 1996
53. Gold J., High HA, Li Y., et al. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 10: 745-752, 1996
54. Berger JR, Pall L., Hall CD, et al. Oxandrolone in AIDS-wasting myopathy.: AIDS 10: 1657-1662, 1996
55. Hengge UR, Baumann M., Maleba R., et al. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br J Nutr 75: 129-138, 1996
56. Berger JR, Pall L., Winfield D.: Effect of anabolic steroids on HIV-related wasting myopathy. South Med J 86: 865-866, 1993
57. Rabkin JG, Rabkin R., Wagner JG: Testosterone treatment of clinical hypogonadism in patients with HIV/AIDS. Int J STD AIDS 8: 537-545, 1997
58. Engelson ES, Rabkin JG, Rabkin R., et al. Effects of testosterone upon body composition. J Acquir Immune Defic Syndr 11: 510-511, 1996
59. Coodley GO, Coodley MK: A trial of testosterone therapy for HIV-Associated weight loss. AIDS 11: 1347-1352, 1997
60. Bhasin S., Storer TW, Kilbourne A., et al. Effects of physiologic testosterone replacement in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 83: 3155-3162, 1998
61. Grinspoon S., Vorcoran C., Askari H., et al. Effects of androgen administration in men with the AIDS wasting syndrome: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 129: 18-26, 1998
62. Miller K., Corcoran C., Armstrong C., et al. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: A pilot study. J Clin Endocrinol Metab 83: 2717-2725, 1998
63. Seidell J., Bjorntorp P., Sjostrom L., et al. Visceral fat accumulation in men is positively associated with insulin. glucose and C-peptide levels, but negatively with testosterone levels. Metabolism 39: 897-901, 1990
64. Barrett-Connors E., Khaw K.-T: Endogenous sex-hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78: 539-545. 1988
65. Marin P. Krotkiewski M. Bjorntorp P.: Androgen treatment of middle-Aged, obese men: effects on metabolism, muscle. and adipose tissues. Eur J Med 1: 329-336, 1992
66. Marin P. Oden B. Bjorntorp P.: Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: Effects of androgens. J Clin Endocrinol Metab 80: 239-2-13, 1995
67. Bartsch W. Krieg M. Voi-gt KD: Quantitation of endogenous testosterone. 5-Alpha-dihydrotestosterone and 5-Alpha-Androstane-3-Alpha. 17-beta-diol in subcellular fractions of the prostate. bulbocavernosus/levator ani muscle. skeletal muscle. and heart muscle of the rat. J Steroid Biochem 13: 259-267, 1980
68. Sattler FR, Antonipillai I., Allen J., et al. Wasting and sex hormones: Evidence for the role of dihydrotestosterone in AIDS patients with weight loss [Abstract Tu. B.2376]. Presented at the XI International Conference on AIDS. Vancouver, Canada. 1996, p 537
69. Dahlberg E., Snochowski M., Gustaffsson JA: Regulation of the androgen and glucocorticoid receptors in the rat and mouse muscle cytosol. Endocrinology 108: 1431-1436, 1981
70. Michel G., Bauheu EE: Androgen receptor in skeletal muscle: Characterization and physiologic variations. Endocrinology 107: 2088, 1980
71. Saartok T., Dahlberg E., Gustaffsson JA: Relative binding affinity of anabolic-Androgenic steroids, comparison of the binding to the androgen receptors in skeletal muscle and in prostate as well as sex hormone binding globulin. Endocrinology 114: 2100-2107, 1984
72. Konagaya M., Max SR: A possible role for endogenous glucocorticoid in orchiectomy-induced atrophy of the rat levator ani muscle: Studies with RU38486, a potent glucocorticoid antagonist. J Steroid Biochem 25: 305-311, 1986
73. Mayer M., Rosen F.: Interaction of anabolic steroids with glucocorticoid receptor sites in rat muscle cytosol. Am J Physiol 229: 1381-1386, 1975
74. Fryburg DA, Weltman A., Jahn LA, et al. Short-Term modulation of the androgen milieu alters pulsatile, but not exercise-or growth hormone (GH)-releasing hormone-stimulated GH secretion in healthy men: impact of gonadal steroid and GH secretory changes on metabolic outcomes. J Clin Endocrinol Metab 82: 3710-3719, 1997
75. Leslie M., Forger NG, Breedlove SM: Sexual dimorphism and androgen effects on spinal motoneurons innervating the rat flexor digitorum brevis. Brain Res 561: 269-273, 1991
76. Blanco CE, Popper P., Micevych P.: Anabolic-Androgenic steroid induced alterations in choline acetyltransferase messenger RNA levels of spinal cord motoneurons in the male rat. Neuroscience 78: 973-882, 1997
77. Zumoff B., Strain GW, Miller LK, et al. Twenty-four hour mean plasma testosterone concentrations declines with age in normal premenopausal women. J Clin Endocrinol Metab 80: 1429-1430, 1995
78. Sherwin B., Gelfand MM, Brender W.: Androgen enhances sexual motivation in females: A prospective, crossover study of sex steroid administration in surgical menopause. Psychosom Med 47: 339-351, 1997
79. Burger HG, Hailes J., Nelson J., et al. Effect of combined implants of estradiol and testosterone on libido in postmenopausal women. Br Med J 294: 936-937, 1987
80. Raisz LG, Wiita B., Artis A., et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 81: 37-43, 1995
81. Watts NB, Notelovitz M., Timmons MC: Comparison of oral estrogens and estrogens plus androgen on bone mineral density. menopausal symptoms and lipid-lipoprotein profile in surgical menopause. Obstet Gynecol 85: 529-537. 1995
82. Sinha-Hikim I., Arver S., Beall G., et al. The use of a sensitive equilibrium dialysis method for the measurement of free testosterone levels in healthy, cycling women and in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 83: 1312, 1998
83. Grinspoon S. Corcoran C. Miller K., et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab 82: 1332-1337, 1997